NBY (NBY)
NovaBay Pharmaceuticals, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
NovaBay Pharmaceuticals, Inc. (NBY) is a pharmaceutical company that specializes in developing and globally distributing products for eyecare and dermatology.
Its product portfolio includes Avenova, an advanced solution designed for cleaning the delicate skin around the eye, such as the eyelids, by removing foreign substances, microorganisms, and debris.
The company also offers wound management solutions under its NeutroPhase and PhaseOne brands. Furthermore, NovaBay provides a variety of dermatological treatments through its DERMAdoctor brand, addressing diverse skin concerns. These include conditions like keratosis pilaris, rosacea, and eczema, as well as anti-aging formulations, SPF protection, remedies for hyperhidrosis (excessive sweating), solutions for unwanted hair, and acne treatments.
The company distributes its products through a multi-channel approach, utilizing traditional retailers, digital beauty platforms, various distributors, and its own online sales channels. Founded in 2000, the company was initially known as NovaCal Pharmaceuticals, Inc., before officially adopting the name NovaBay Pharmaceuticals, Inc. in February 2007.
Its corporate headquarters are located in Emeryville, California.
Leadership
David E. Lazar
Chief Executive Officer of NovaBay
Justin M. Hall, Esq.
Director
Mijia (Bob) Wu, M.B.A.
Director
Mr. Hall
Vice President of Business Development, General Counsel and Corporate Secretary
Employees
13
Country
US
Sector
Healthcare
Website
novabay.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| 10% Owner | Conversion of Derivative | 56.81M | -- | Oct 21, 2025 | |
| 10% Owner | Conversion of Derivative | 56.81M | -- | Oct 21, 2025 | |
| 10% Owner | Option Exercise | 39.9K | -- | Oct 21, 2025 | |
| 10% Owner | Grant/Award | 6.39M | -- | Oct 21, 2025 | |
| Chief Executive Officer | Conversion of Derivative | 56.81M | -- | Oct 21, 2025 | |
| 10% Owner | Sale | 441.3K | -- | Oct 16, 2025 |
| Name | Shares | % | Source |
|---|---|---|---|
Kazley Michael John · joint filing· may incl. warrants· filed Jul 2026 | 53.6M | 52.4% | 13D |
Framework Ventures IV L.P. · joint filing· may incl. warrants· filed Jul 2026 | 47.7M | 46.6% | 13D |
R01 Fund LP 10% Owner | 22.7M | -- | FORM 4 |
Sky Frontier Foundation · filed Sep 2026 | 0+5.6M via warrants | 9.9% | 13D |
David E. Lazar · may incl. warrants· filed Jan 2026 | 1.3M | 5.0% | 13D |
BlackRock, Inc. | 424.7K | -- | 13F |
VANGUARD CAPITAL MANAGEMENT LLC | 327.0K | -- | 13F |
GEODE CAPITAL MANAGEMENT, LLC | 281.5K | -- | 13F |
Poplar Point Capital Management LLC · may incl. warrants· filed Mar 2026 | 204.1K | 0.8% | 13D |
POPLAR POINT CAPITAL PARTNERS LP 10% Owner | 204.1K | -- | FORM 4 |
Insiders
- R01 Fund LP10% Owner
- Framework Ventures IV L.P.10% Owner
- Lazar David E.10% Owner
- Kazley Michael JohnChief Executive Officer
- POPLAR POINT CAPITAL PARTNERS LP10% Owner
30d Avg
--
60d Avg
--
90d Avg
--